Choosing Your Business Model

Before drafting financial projections, most genotyping founders need to settle a more basic question: are you running the assay yourself, or coordinating collection and reporting around someone else's lab? The three models that show up repeatedly in real business plans each have a distinct capital requirement, timeline, and margin profile, and picking the wrong one for your stage is a common reason plans get rejected by lenders who can tell the numbers don't match the model described.

Model 1 — Asset-Light Referral / Collection Service

You handle sample collection, client relationships, chain-of-custody, and reporting, while a contracted CLIA (or UKAS-accredited) lab runs the actual genotyping assay. Startup capital is typically $75,000–$180,000, covering a collection kit inventory, a small office or mobile collection setup, and client-facing software. You earn a collection/handling margin — commonly $40–$90 per sample — rather than the full test price, but you're also not carrying instrument depreciation or direct accreditation costs. This is the fastest route to revenue, often within 60–90 days of forming the business, because you're not waiting on your own CLIA or UKAS certificate.

Model 2 — In-House Targeted PCR/TaqMan Genotyping

You run a defined marker panel yourself on a qPCR platform — the model most agricultural, veterinary, and small clinical-panel businesses choose. Startup capital runs $180,000–$500,000 once instruments, extraction automation, LIMS, facility fit-out, and accreditation are included. You control turnaround time and can differentiate on service, but you're now the one managing CLIA/UKAS compliance directly, with 3–6 months of lead time before you can bill your first sample.

Model 3 — In-House Array-Based High-Throughput Genotyping

You run Illumina Infinium (or equivalent) arrays capable of processing hundreds of thousands of markers per sample, typically serving research core-facility clients, large agricultural breeding programs, or high-density clinical panels. Startup capital runs $500,000–$950,000+ once the array reader, automation, and a properly sized LIMS/bioinformatics stack are included. This model has the highest ceiling and the highest fixed cost — it only makes sense once you have committed volume (an institutional contract, a breed registry partnership, or a multi-year referral agreement) large enough to justify the depreciation.

Most first-time founders should start with Model 1 or Model 2 and graduate to Model 3 once volume genuinely requires it — the case study later in this guide follows exactly that path, moving from a targeted PCR launch toward array capacity as volume grew past 450 samples/month.

Equipment & Lab Setup Checklist

Before you write a single financial projection, decide which genotyping method your business is actually built around, because the equipment list — and therefore the capital you need — changes dramatically depending on the answer. A targeted PCR/TaqMan setup for a defined marker panel looks nothing like an Illumina Infinium array line built to run hundreds of thousands of markers per sample. Most successful business plans in this space pick one method and go deep rather than trying to offer both from day one.

• Real-time PCR / qPCR thermocycler: $18,000–$60,000 — the entry point for targeted SNP genotyping and the most common first purchase for a lean launch
• Array reader / BeadChip scanner (if running Illumina-style arrays): $120,000–$400,000, plus the arrays themselves at $78–$1,172 per sample depending on marker density
• Automated liquid handling / DNA extraction robot: $40,000–$180,000 — cuts labor cost per sample once volume exceeds roughly 200 samples/month
• Sample storage (-80°C freezers, LN2 tanks for archival): $8,000–$35,000
• LIMS (laboratory information management system) & bioinformatics server/storage: $15,000–$150,000 depending on whether you license a hosted LIMS or build server infrastructure in-house
• QC instrumentation (spectrophotometer, fluorometer for DNA quantitation): $12,000–$45,000
• Biosafety cabinet & general lab bench fit-out: $25,000–$90,000
• Sample collection kits (swabs, tubes, mailers) if running a mail-in model: $2–$6 per kit at volume

A lean launch built around targeted PCR genotyping — one thermocycler, an extraction robot, and a hosted LIMS — can be assembled for roughly $100,000–$220,000 in instruments alone. Moving to an Illumina array platform to serve higher-density panels (agricultural breeding values, pharmacogenomic panels, or research core-facility work) pushes the equipment line closer to $400,000–$750,000 before facility costs are added. Neither figure includes the CLIA/CAP or UKAS accreditation process covered below, which has its own timeline independent of when the equipment physically arrives.

Facility layout matters more than founders usually budget for. A genotyping lab needs physically separated pre-PCR (sample accessioning, extraction) and post-PCR (amplification, detection) workspaces to avoid contamination between batches — retrofitting this into an existing office footprint after the fact typically costs 30–50% more than designing it into the original fit-out. Ventilation, bench-top power capacity for thermocyclers and freezers, and a dedicated waste-disposal contract for biological consumables are the three line items most first-time genotyping business plans miss entirely, and they are exactly what a lab-design contractor or accreditation assessor will flag first during a site visit.

Whichever platform you choose, buy for the volume you'll actually run in Year 2, not Year 1. Array readers and high-throughput liquid handlers carry meaningful fixed depreciation whether you run 50 samples a month or 5,000, so oversizing the platform early is one of the fastest ways to turn a promising genotyping business plan into a cash-flow problem before revenue catches up.

Startup Costs & Funding Routes

Launching a genotyping business typically requires $180,000 to $950,000 in the US (£140,000 to £750,000 in the UK), with the wide range driven almost entirely by whether you're building an asset-light referral model on top of a partner lab or standing up your own certified facility. An asset-light model — where you handle collection, client relationships, and reporting while a contracted CLIA lab runs the actual assay — can realistically launch closer to $100,000, since you're financing collection kits, a small office, and software rather than instruments.

UK founders importing US- or EU-manufactured instruments (Illumina, Thermo Fisher, and Agena all manufacture outside the UK) should budget for import duty and VAT on top of the sticker price, plus a weaker exchange rate buffer — a 5–8% contingency on the equipment line is standard practice in the plans we build for UK genotyping clients. Domestic UK suppliers of extraction consumables and general lab plasticware can offset some of this, but the core genotyping instrument itself is almost always an import.

Cost Breakdown (In-House Lab Model)

• Genotyping platform (PCR line or array reader + supporting instruments): $60,000–$750,000 (£47,000–£590,000)
• Automation & liquid handling / extractors: $40,000–$400,000 (£31,000–£315,000)
• LIMS, server & bioinformatics storage: $15,000–$150,000 (£12,000–£118,000)
• CLIA/CAP certification, state licensing & accreditation (initial): $10,000–$50,000, plus roughly $1,000/month ongoing
• Facility fit-out to lab-grade standard: $80,000–$600,000 (£63,000–£473,000)
• Reagents, consumables & QC materials (first 6 months): $20,000–$120,000 (£16,000–£95,000)

Funding Routes

In the US, an SBA 504 loan is the natural fit for the equipment- and facility-heavy side of a genotyping launch, since 504 loans are specifically structured for major fixed assets like lab instruments and building improvements, typically covering up to 90% of project cost when combined with a bank loan and a smaller owner contribution. A standard SBA 7(a) loan is more commonly used for working capital, staff, and early reagent stock. Under NAICS 621511 (Medical Laboratories) — the classification code that covers DNA testing and genetic testing labs — the SBA small-business size standard is $42 million in average annual receipts, meaning almost every genotyping startup qualifies as a small business for SBA purposes.

In the UK, the Start Up Loans scheme offers up to £25,000 per founder at 6% fixed interest with free mentoring, which rarely covers a full lab build alone but works well layered under equipment finance or an Innovate UK smart grant for founders building novel diagnostic or agricultural genotyping technology. Because instrument and facility costs dominate this budget, our bespoke business plan service builds the itemized, lender-ready cost schedule that SBA 504 and equipment-finance underwriters specifically ask for.

Cash-flow timing is the part most founders underestimate: accreditation, facility fit-out, and instrument procurement all happen before a single billable sample is processed, which means 4–9 months of spend with zero revenue is normal, not a sign the plan is wrong. Lenders reviewing a genotyping application specifically look for a cash-flow schedule that shows this pre-revenue period funded explicitly — through working capital reserves or a drawn-down loan structure — rather than assumed away. Plans that skip this step are the ones that come back from an SBA loan committee with follow-up questions instead of an approval.

Instrument & Reagent Suppliers

Unlike a restaurant or retail startup, a genotyping business plan lives or dies on which instrument and reagent partners you name — lenders and investors will check whether your platform choice actually matches your target market. The table below covers the suppliers that show up most often in real genotyping business plans, split by the segment they serve best.

The Neogen/GeneSeek acquisition is worth understanding even if you're not in agriculture: Zoetis paid $160 million for a genomics business running five laboratories across the US, Brazil, Australia, China, and the UK, serving customers in more than 120 countries — a reminder that scaled competitors can absorb regional genotyping operators quickly, and that a defensible niche (a specific species, breed registry, or clinical panel) matters more than trying to out-compete Illumina or Thermo Fisher on price per sample.

Most business plans in this space name one platform partner (Illumina, Thermo Fisher, LGC, or Agena) and one extraction/automation partner (often Qiagen or Hamilton), then treat everything downstream — reporting, client portals, billing — as software the founder builds or licenses separately. Naming these choices explicitly in your plan, rather than leaving "lab equipment" as a single undifferentiated line item, is one of the fastest ways to make a genotyping business plan read as credible to a lender who has seen dozens of vague diagnostics pitches.

Contract terms matter as much as list pricing. Reagent and array suppliers typically offer volume discounts once a lab commits to an annual purchase agreement, which is worth negotiating before you finalize your revenue forecast rather than after — a 10–15% reagent discount tied to a minimum annual order can be the difference between an 8% and a 15% net margin on the same sample volume. Ask prospective suppliers for a tiered quote at your Year 1, Year 2, and Year 3 projected volumes before you lock in the numbers your business plan will show a lender.

Licensing, Accreditation & Compliance

United States

• CLIA certification through CMS — required if results go back to a patient, physician, or clinical record; $10,000–$50,000 initial plus roughly $1,000/month ongoing, taking 3–6 months
• CAP accreditation (voluntary but often expected by referring physicians and insurers) — biennial inspection cycle through the College of American Pathologists
• State clinical laboratory permit — some states (New York's CLEP scheme is the best-known example) require separate out-of-state lab permitting if you test residents of that state, adding 2–4 months
• GINA & HIPAA compliance for handling genetic data and preventing discriminatory use of results
• Purely research-use-only or agricultural/veterinary genotyping generally sits outside CLIA, but CAP-style quality standards are still commercially expected

United Kingdom

• UKAS ISO 15189:2012 Medical Laboratory Accreditation — £8,000–£39,000 depending on scope, 6–12 months from application to assessment
• UKCA marking for in-vitro diagnostic devices via MHRA, typically £5,000–£25,000 in conformity assessment costs depending on device risk class
• UK GDPR treats genetic data as special category data under Article 9, requiring explicit consent and a documented lawful basis before processing
• Human Tissue Authority (HTA) licensing may apply if you store or process certain human tissue-derived samples beyond straightforward DNA extraction

European Union

Genotyping kits or services sold as diagnostic products into the EU fall under the In Vitro Diagnostic Regulation (IVDR 2017/746) rather than the older IVDD, requiring CE marking with staggered transitional deadlines by device risk class extending toward 2027–2029 for existing devices. If EU expansion is part of your 3–5 year plan, build the IVDR conformity assessment timeline into your roadmap now — it's a common gap in genotyping business plans that only budget for US/UK compliance.

Sequencing the paperwork correctly matters as much as the paperwork itself. A realistic order of operations is: form the legal entity and secure the lease first, apply for CLIA (or UKAS accreditation) as soon as the space is fit-out-ready rather than waiting for equipment to arrive, and run validation samples during the inspection waiting period so the lab can start billing the week certification lands. Businesses that treat accreditation as the last step instead of a parallel track routinely lose two to four months of otherwise-avoidable downtime.

Revenue Model & Sample Economics

Genotyping pricing varies more by marker density and method than almost any other diagnostics category. On Illumina Infinium arrays, per-sample pricing runs from about $78 for a basic QC array (roughly 15,000–16,000 markers) up to $1,172 for a CoreExome array covering 664,000-plus markers. Targeted TaqMan SNP assays typically cost $0.30–$1.47 per SNP per sample depending on volume and whether the assay is custom-designed, and high-volume agricultural panels (aquaculture genotyping in particular) can fall as low as $16 per sample at real scale.

A lab running 600 samples/month on a mid-density array at $180/sample generates $108,000 in monthly gross billings — roughly $1.3 million a year. Reagents and consumables typically consume 40–50% of that revenue, staff and QC another 30–35%, leaving a net margin of 8–18% once facility costs, compliance overhead, and instrument depreciation are covered. That margin band is tighter than most diagnostics categories because reagent and array cost is the single largest variable line — it's why differentiated positioning (a specific breed registry, a clinical panel with a referral pipeline, or a research core facility with recurring institutional contracts) matters more here than in most service businesses.

Recurring revenue is the structural advantage worth building in from day one. 23andMe's March 2025 Chapter 11 filing was driven by a 2023 data breach and, more fundamentally, by a one-time-purchase consumer model with no recurring layer once ancestry-kit demand cooled. Businesses that pair genotyping with subscription or repeat-testing revenue — annual breeding-value panels for livestock producers, pharmacogenomic panels tied to ongoing prescribing decisions, or research core-facility service contracts — have kept growing through the same period.

The asset-light referral model produces a very different economic shape worth modeling separately. If you collect samples and route them to a partner CLIA lab rather than running your own instruments, you typically keep a collection/handling fee of $40–$90 per sample rather than the full test price, with the partner lab invoicing the client (or you) directly for the assay itself. At 300 samples/month and a $60 handling fee, that's $18,000 in monthly gross revenue against overhead that's a fraction of an in-house lab's — often 35–45% net margin, well above the in-house model, because you're not carrying instrument depreciation or CLIA compliance costs directly. The trade-off is lower ceiling: you can't easily differentiate on turnaround time or panel design when someone else's lab controls the queue.

The Genotyping Market in 2026

The global genotyping market is projected to reach $91.85 billion by 2035, according to Precedence Research, growing at a 13.62% compound annual rate. The US market specifically is forecast to hit $26.53 billion by 2034 at a 13.72% CAGR, driven by pharmacogenomics, agricultural genomics, and expanding clinical panels, per Straits Research.

In the UK, the genetic testing market was valued at approximately $790.15 million in 2025, projected to reach $4.432 billion by 2035 at an 18.8% CAGR, per Market Research Future — faster relative growth than the US market, reflecting NHS Genomic Medicine Service expansion and continued government investment through Genomics England.

Three forces are shaping demand: agricultural and veterinary genotyping is consolidating fast (Zoetis's $160 million purchase of Neogen's GeneSeek genomics business in 2026 is the clearest signal), pharmacogenomics is pulling genotyping into routine prescribing decisions rather than one-off consumer purchases, and the direct-to-consumer ancestry segment that made 23andMe and AncestryDNA household names has cooled sharply since 23andMe's 2025 bankruptcy. For a new business plan, that means the strongest opportunities in 2026 sit in B2B, agricultural, and clinical-panel genotyping rather than in trying to re-enter the DTC ancestry space against incumbents with sunk brand costs and declining demand.

In the UK specifically, the government's continued backing of Genomics England and the NHS Genomic Medicine Service — building on the original 100,000 Genomes Project — has pushed pharmacogenomic and rare-disease genotyping into mainstream NHS pathways rather than leaving it as a private-pay niche. That creates a credible commissioning route for UK genotyping businesses that can meet UKAS accreditation and NHS procurement standards, which is a materially different go-to-market than the private-pay, cash-only model most US genotyping startups default to. On the reimbursement side in the US, genotyping panels billed under recognized CPT codes to insurers behave very differently from cash-pay consumer tests — insurer reimbursement rates and claim denial risk should be modeled explicitly in your financial forecast rather than assumed at the cash-pay price point.

If your plan sits closer to a broader diagnostics offer rather than genotyping specifically, our DNA testing business plan template covers the wider DNA testing category, including paternity and forensic-adjacent services that fall outside pure genotyping.

Estimate Your Own Sample Economics

Because per-sample cost and price vary so widely across genotyping methods, a generic industry margin figure isn't much use for your own plan. Plug in your expected monthly sample volume, your price per sample, your reagent/consumable cost per sample, and your fixed monthly overhead (staff, rent, compliance) to see your own gross billings and margin.

This is a simplified model for planning purposes only — it doesn't account for instrument depreciation, one-off accreditation costs, or seasonal volume swings. Our $300/£250 Research + Content package builds the full 5-year forecast with those factors included.

Sample Business Plan Preview

Here's an extract from a business plan structured for a genotyping launch — so you can see exactly what a lender-ready version looks like:

What's in the Template

Every Avvale genotyping business plan template includes these sections, pre-structured for your specific launch model:

• Executive Summary — Your genotyping business at a glance, written to hook a lender or investor in 60 seconds
• Company Overview — Legal structure, ownership, lab location, and CLIA/UKAS certification status or roadmap
• Industry Analysis — Market size, growth trends, and the regulatory landscape specific to genotyping (not generic healthcare boilerplate)
• Customer Analysis — Target segments (clinical referral, agricultural/veterinary, research core-facility, or B2B), spending patterns, and volume assumptions
• Competitor Analysis — Positioning against scaled players like Illumina, Thermo Fisher, and Neogen/GeneSeek, and where a smaller operator can win
• Marketing Plan — Referral-channel strategy for clinical, veterinary, or research clients
• Operations Plan — Sample intake, chain-of-custody, turnaround-time commitments, and LIMS workflow
• Management Team — Founder scientific credentials, lab director qualifications, and key hires planned

Every section is pre-populated with genotyping-specific placeholder language and prompts — not blank headers — so you're editing real sentences with your own numbers rather than staring at an empty page. The Industry Analysis section, for example, already references NAICS 621511, the SBA size standard, and the CLIA/UKAS accreditation timeline, so you're refining detail rather than starting from zero.

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and instrument-by-instrument capital requirements — the level of detail SBA 504 and equipment-finance underwriters specifically ask genotyping applicants for.

The $5/£5 template gives you the full structure and section prompts to write the plan yourself, which is the right choice if you already have a strong grasp of your numbers and just need the document architecture. The $300/£250 Research + Content tier adds our team writing the narrative sections and pulling the market data for you, while keeping the financial forecast as a template you populate. The $1,000/£800 Bespoke Plan is the option most genotyping founders going to an SBA lender or an institutional investor choose, because it includes a fully built 5-year forecast reviewed by our team against exactly the kind of equipment-specific, NAICS-anchored detail this guide has walked through — the difference between a plan that reads as generic and one that reads as investor- or lender-ready on first pass.

Common Launch Mistakes

Most genotyping business plans that stall or get rejected by lenders share a small set of avoidable errors. These show up repeatedly whether the founder is targeting clinical, agricultural, or research-market genotyping:

• Competing purely on price per sample against Illumina- or Thermo Fisher-scale suppliers instead of building a defensible niche — a specific species, breed registry, or clinical panel where a smaller operator can win on turnaround time or relationship depth
• Underestimating the CLIA/CAP or UKAS timeline and signing a lease or hiring lab staff before the certificate is realistically in hand, burning payroll with no billable revenue
• Copying the 23andMe direct-to-consumer, one-time-purchase model without a recurring revenue layer — re-testing, panel upgrades, or breeding-value subscriptions — to survive a demand slowdown
• Under-budgeting for LIMS and bioinformatics infrastructure, which is easy to treat as an afterthought but is often 10–15% of total capex once server, storage, and reporting-software costs are totaled
• Ignoring UK/EU IVD transitional deadlines when planning to sell kits or services across borders, creating a compliance gap mid-operation that surfaces only when a client asks for proof of CE marking
• Sizing the platform for launch volume rather than Year 2 volume, which either strands capital in an oversized array reader or forces an expensive equipment upgrade sooner than the forecast assumed

None of these are unique insights available only to Avvale — they're the same issues an experienced lab-startup consultant or SBA loan officer would flag on a first read. What actually moves a genotyping business plan from "generic" to fundable is showing, with real numbers, that you've already priced these risks into your cost schedule and timeline rather than leaving them as open questions.

Frequently Asked Questions

Related Reading

Exploring the wider startup toolkit? See our business plan writer service for one-on-one help, or browse the full library of free business plan templates across every industry we cover. If your launch spans both genotyping and broader diagnostic testing, our team can also scope a combined plan covering both service lines rather than treating them as separate documents — useful for founders building a lab that runs targeted panels alongside general DNA testing referrals.